Literature DB >> 3156931

Characterization of a soluble form of the C3b/C4b receptor (CR1) in human plasma.

S H Yoon, D T Fearon.   

Abstract

A radioimmunoassay with the use of soluble 125I-Fab monoclonal anti-CR1 and rabbit IgG anti-CR1 bound to Staphylococcus aureus particles was employed to detect and quantitate CR1 antigen in human plasma. Among 16 normal individuals the concentration of soluble CR1 in plasma ranged from 13 to 81 ng/ml, and a similar range of concentration was found in plasma from 15 patients having systemic lupus erythematosus (SLE). The amount of plasma CR1 in normal donors, but not in SLE patients, significantly correlated with the number of CR1 sites on erythrocytes (r = 0.90, p less than 0.001), and was 7.1% of the amount of receptor that was present on erythrocytes in blood. The concentration of soluble CR1 was not diminished by ultracentrifugation or ultrafiltration of plasma, was not affected by various modes of anti-coagulation or even by clotting of blood, and did not change during incubation of blood at 4 degrees C for up to 4 hr. On sucrose density gradient ultracentrifugation of plasma the CR1 was distributed as a broad peak that overlapped the plasma protein profile. The Mr of plasma CR1 was identical to that of erythrocyte CR1 when assessed by polyacrylamide gel electrophoresis in the presence of sodium dodecyl sulfate and immunoblotting. In addition, the plasma form of CR1 exhibited the same structural phenotype as did receptor from erythrocytes of the same individual. CR1 antigen purified from plasma was as active as CR1 from erythrocytes in promoting the cleavage by factor I of C3b to iC3b, C3c, and C3dg. Therefore, a functionally and structurally intact form of soluble CR1 resides in plasma.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3156931

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  28 in total

1.  The ontogenesis of Fc gamma receptors and complement receptors CR1 in human peripheral nerve.

Authors:  C A Vedeler; E Scarpini; S Beretta; R Doronzo; R Matre
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

2.  Soluble form of complement C3b/C4b receptor (CR1) results from a proteolytic cleavage in the C-terminal region of CR1 transmembrane domain.

Authors:  I Hamer; J P Paccaud; D Belin; C Maeder; J L Carpentier
Journal:  Biochem J       Date:  1998-01-01       Impact factor: 3.857

Review 3.  Surface proteins and glycoproteins of human leucocytes.

Authors:  V Horejsí; V Bazil
Journal:  Biochem J       Date:  1988-07-01       Impact factor: 3.857

Review 4.  CR1 in Alzheimer's disease.

Authors:  Xi-Chen Zhu; Jin-Tai Yu; Teng Jiang; Ping Wang; Lei Cao; Lan Tan
Journal:  Mol Neurobiol       Date:  2014-05-04       Impact factor: 5.590

5.  The complete amino acid sequence of human complement factor H.

Authors:  J Ripoche; A J Day; T J Harris; R B Sim
Journal:  Biochem J       Date:  1988-01-15       Impact factor: 3.857

6.  Complement factor H-binding protein of Raji cells and tonsil B lymphocytes.

Authors:  A Erdei; R B Sim
Journal:  Biochem J       Date:  1987-08-15       Impact factor: 3.857

Review 7.  CR1 and the cell membrane proteins that bind C3 and C4. A basic and clinical review.

Authors:  J G Wilson; N A Andriopoulos; D T Fearon
Journal:  Immunol Res       Date:  1987       Impact factor: 2.829

8.  Cellular origins of serum complement receptor type 2 in normal individuals and in hypogammaglobulinaemia.

Authors:  N Ling; T Hansel; P Richardson; B Brown
Journal:  Clin Exp Immunol       Date:  1991-04       Impact factor: 4.330

9.  Autoantibody to the C3b/C4b receptor and absence of this receptor from erythrocytes of a patient with systemic lupus erythematosus.

Authors:  J G Wilson; R M Jack; W W Wong; P H Schur; D T Fearon
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

10.  C3b receptor (CR1) genomic polymorphism in rheumatoid arthritis. Low receptor levels on erythrocytes are an acquired phenomenon.

Authors:  A Kumar; A N Malaviya; S Sinha; P S Khandekar; K Banerjee; L M Srivastava
Journal:  Immunol Res       Date:  1994       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.